

Supplementary

S1




Figure S1. qRT-PCR analysis of IL-1β expression on OB derived by KL>3 group (A) and KL ≤ 3 group (B) treated :with IL-1β , after transfection with miR203a-3p inhibitor, after co-treatments IL-1β and miR203a-3p inhibitor. Data are reported as FOI of expression between treated and untreated samples. (Mean \pm SD, n=4). Student’s t- test: 1 symbol, $p < 0.05$; 2 symbols, $p < 0.005$; 3 symbols, $p < 0.0005$.

Supplementary

S2




Figure S2. qRT-PCR analysis of CX-43 expression on OB derived by KL>3 group and KL ≤3 group treated with IL-1β, after transfection with miR203a-3p inhibitor, after co-treatments IL-1β and miR203a-3p inhibitor. Data are reported as FOI of expression between interleukin treated and inhibitor miR203a-3p transfected cells versus interleukin treated cells (Mean ± SD, n=4). Student's t- test: 1 symbol, p < 0.05; 2 symbols, p < 0.005; 3 symbols, p < 0.0005.

S3




Figure S3: Percentage of methylation of two methyl-sensible restriction sites through MSRE-PCR analyses of IL-8 promoter of MSCs after 48 hrs under to the following treatments: Untreated; IL-1β (10 ng/ml); IL-1b (20 ng/ml); (Mean ± SD, n = 3, duplicates).